SPOTLIGHT -
Novel gene therapy EG-70 nears 75% complete response rate in NMIBC
EG-70 is an experimental intravesical immunotherapy that does not involve viruses or integration. It aims to eliminate tumors by triggering coordinated innate and adaptive immune reactions specifically within the bladder.
Investigators report on real-world recurrence, survival rates in RCC
“Our study provides real-world recurrence and survival rates, [however], a major limitation is the retrospective nature of the analysis,” wrote the investigators, led by Viktor Gruenwald, MD, PhD.